Ratings Shattuck Labs, Inc.

Equities

STTK

US82024L1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
7.26 ^USD	-1.76%		-2.02%	+1.82%

May. 14	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of Sl-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (Hr-Mds) and Tp53 Mutant Acute Myeloid Leukemia Patients At the European Hematology Association 2024 Congress	CI
May. 02	Shattuck Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
SHATTUCK LABS, INC.	+1.82%	351M	D+
MODERNA, INC.	+55.55%	59.34B	B-
LONZA GROUP AG	+43.17%	40.24B	A
IQVIA HOLDINGS INC.	-4.71%	39.88B	B
CELLTRION, INC.	-5.56%	28.55B	C
ICON PUBLIC LIMITED COMPANY	+13.76%	27.26B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.00%	19.23B	B
MEDPACE HOLDINGS, INC.	+31.50%	12.61B	C+
BIO-TECHNE CORPORATION	+2.16%	12.49B	B+
UNITED THERAPEUTICS CORPORATION	+25.70%	12.28B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes